Know Cancer

or
forgot password

Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)


N/A
18 Years
75 Years
Not Enrolling
Both
Myelodysplastic Syndromes, Myeloproliferative Disorders, Blood and Marrow Transplant (BMT), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD)

Thank you

Trial Information

Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)


Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of
Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)


Inclusion Criteria:

- Myelodysplastic Syndromes

- Myeloproliferative Disorders

- HLA matched donor available

Exclusion Criteria:- organ dysfunction

- HIV positive

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy of transplant

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Ginna Laport

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

BMT128

NCT ID:

NCT00186576

Start Date:

December 2001

Completion Date:

July 2010

Related Keywords:

  • Myelodysplastic Syndromes
  • Myeloproliferative Disorders
  • Blood and Marrow Transplant (BMT)
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Disorders (MPD)
  • Myelodysplastic Syndromes
  • Preleukemia
  • Myeloproliferative Disorders

Name

Location

Stanford University School of MedicineStanford, California  94305-5317